Đang tải... (xem toàn văn)
(BQ) Part 2 book Litt''s drug eruption reference manual including drug interactions presents the following contents: Drugs responsible for common reaction patterns, drugs responsible for common reaction patterns, alphabetical index of drug eruptions A–Z
ABACAVIR (2006): Castillo SA+, Drug Saf 29(9), 811 (16%) (with lamivudine) ABACAVIR Trade names: Trizivir (GSK); Ziagen (GSK) Indications: HIV infections in combination with other antiretrovirals Category: Antiretroviral; Nucleoside analog reverse transcriptase inhibitor Half-life: 1.5 hours Clinically important, potentially hazardous interactions with: arbutamine, argatroban, arsenic Reactions Skin Acute febrile neutrophilic dermatosis (Sweet’s syndrome) (2004): Del Giudice P+, J Am Acad Dermatol 51(3), 474 Edema (1999): Spruance SL, Skin and Allergy News October, 37 Erythema multiforme Erythroderma (2001): Shapiro M+, The AIDS Reader 11, 222 Exanthems (1999): Nathanson N (generalized) (from Internet) (observation) (1999): Spruance SL, Skin and Allergy News October, 37 (1998): Saag M+, AIDS 12, F203 Pruritus (1998): Saag M+, AIDS 12, F203 Rash (sic) (10–69%) (2003): Lanzafame M+, Infez Med 11(1), 40 (2002): Kessler HA+, Clin Infect Dis 34(4), 535 (2001): Hetherington S+, Clin Ther 23(10), 1603 (2000): Hervey PS+, Drugs 60, 447 (5%) (1999): Hughes W+, Antimicrob Agents Chemother 43, 609 (9%) (1999): Spruance SL, Skin and Allergy News October, 37 (69%) (1998): Foster RH+, Drugs 55, 729 (1998): Kessler H+, 36th Meeting of the Infectious Disease Society of America, Denver Abstract 453 (10–15%) (1998): Saag M+, AIDS 12, F203 (10–15%) (1998): Staszewski S+, AIDS 12, F197 (10–15%) Stevens–Johnson syndrome (2002): Bossi P+, Clin Infect Dis 35(7), 902 Toxic epidermal necrolysis Mucosal/ENT Mucocutaneous lymph node syndrome (Kawasaki syndrome) (2002): Toerner JG+, Clin Infect Dis 34(1), 131 Oral ulceration (1999): Spruance SL, Skin and Allergy News October, 37 Oral vesiculation (2002): Fantry LE+, AIDS Patient Care STDS 16(1), Other Anaphylactoid reactions/Anaphylaxis (3%) (2001): Frissen PH+, AIDS 15, 289 (1999): Spruance SL, Skin and Allergy News October, 37 (3–4%) (1999): Walensky RP+, AIDS 13, 999 Chills (1999): Escaut L+, AIDS 13, 1419 Cough (2002): Peyriere H+, Allerg Immunol (Paris) 34(10), 359 (2001): Hetherington S+, Clin Ther 23(10), 1603 (10%) Death (2003): Peyriere H+, Ann Pharmacother 37(10), 1392 (1.8%) Fever (2003): Lanzafame M+, Infez Med 11(1), 40 Headache Hypersensitivity (5%) (2007): Luther J+, Am J Clin Dermatol 8(4), 221 (2006): James JS, AIDS Treat News 419, (2006): Moreno-Cuerda VJ+, Med Clin (Barc) 126(19), 744 (2006): Rauch A+, Clin Infect Dis 43(1), 99 (8%) (2006): Stekler J+, AIDS 20(9), 1269 (2003): Easterbrook PJ+, HIV Med 4(4), 321 (2003): Lanzafame M+, Infez Med 11(1), 40 (2003): Peyriere H+, Ann Pharmacother 37(10), 1392 (8.5%) (2002): AIDS Patient Care STDS 16(5), 242 (2002): Clay PG, Clin Ther 24(10), 1502 (2002): Dargere S+, AIDS 16(12), 1696 (2002): Flexner C, Hopkins HIV Rep 14(3), (2002): Hetherington S+, Lancet 359(9312), 1121 (2002): Hewitt RG, Clin Infect Dis 34(8), 1137 (3.7%) (2002): Kessler HA+, Clin Infect Dis 34(4), 535 (2002): Mallal S+, Lancet 359, 727 (5%) (2002): Phillips EJ+, AIDS 16(16), 2223 (2002): Symonds W+, Clin Ther 24(4), 565 (2002): Toerner JG+, Clin Infect Dis 34(1), 131 (2001): Cutrell A+, International AIDS Society Conference on HIV Buenos Aires Abstract 527 (2001): Frissen PH+, AIDS 15, 289 (2001): Hetherington S, AIDS Read 11(12), 620 (2001): Hetherington S+, Clin Ther 23(10), 1603 (4.3%) (2001): Keiser P+, 8th Conferences on Retroviruses (Chicago) Abstract 622 (2001): Loeliger AE+, AIDS 15(10), 1325 (2001): Peyriere H+, Ann Pharmacother 35(10), 1291 (2001): Shapiro M+, The AIDS Reader 11, 222 (2001): Wit FW+, AIDS 15(18), 2423 (2000): AIDS Read 10, 525 (2000): AIDS Treat News 337, (2000): Prescrire Int 9, 67 (2000): Clay PG+, Ann Pharmacother 34, 247 (2000): GlaxoWellcome, Important Drug Warning July (severe or fatal) (2000): Hervey PS+, Drugs 60, 447 (3–5%) (2000): Keiser P+, Conference on Retroviruses & Opportunistic Infections (Chicago) Abstract 622 (1999): Escaut L+, AIDS 13, 1419 (1999): Miller JL, Am J Health Syst Pharm 56, 304 (1998): AIDS Patient Care SDS 12, 405 (1998): Newsline People AIDS Coalit N Y Feb, 35 (1998): Foster RH+, Drugs 55, 729 (2–3%) (1998): Saag M+, AIDS 12, F203 (2–5%) (1998): Staszewski S+, AIDS 12, F197 (1997): James JS, AIDS Treat News 285, 1, Lipoatrophy (2005): Nolan D+, Sex Health 2(3), 153 (2004): McComsey GA+, Clin Infect Dis 38(2), 263 Lipodystrophy (2002): Bernasconi E+, J Acquir Immune Defic Syndr 31(1), 50 Myalgia/Myositis/Myopathy/Myotoxicity (1999): Escaut L+, AIDS 13, 1419 (1999): Spruance SL, Skin and Allergy News October, 37 Nephrotoxicity (2006): Ahmad M, J Postgrad Med 52(4), 296 (Fanconi syndrome) Paresthesias Rhabdomyolysis (2005): Fontaine C+, AIDS 19(16), 1927 (with ciprofibrate) Vertigo (2006): Castillo SA+, Drug Saf 29(9), 811 (27%) (with lamivudine) ABARELIX ABARELIX ABCIXIMAB Trade name: Plenaxis (Praecis) Indications: Prostate cancer (advanced) Category: Gonadotropin-releasing hormone antagonist Half-life: 13.2 days Clinically important, potentially hazardous interactions with: amiodarone, procainamide, quinidine, sotalol Synonym: C7E3 Trade name: ReoPro (Lilly) (Centocor) Indications: Thrombotic arterial disease Category: Antiplatelet; Glycoprotein IIb / IIIa inhibitor Half-life: 10–30 minutes – given intravenously Clinically important, potentially hazardous interactions with: fondaparinux, reteplase Reactions Reactions Skin Allergic reactions (sic) (2006): Beer TM+, Anticancer Drugs 17(9), 1075 Cellulitis Herpes simplex Peripheral edema (15%) Pruritus Urticaria Skin Acute generalized exanthematous pustulosis (AGEP) Allergic reactions Cellulitis (0.3%) Edema (2002): Pharand C+, Pharmacotherapy 22(3), 380 Hemorrhage (2002): Choi RK+, Mayo Clin Proc 77(12), 1340 Other Asthenia (10%) Gynecomastia (30%) Headache (12%) Hot flashes (79%) Pain (31%) Upper respiratory infection (12%) Vertigo (12%) Peripheral edema (1.6%) Petechiae (0.3%) Pruritus (0.3%) (2002): Pharand C+, Pharmacotherapy 22(3), 380 Mucosal/ENT Gingival bleeding (2005): Lee DH+, Acta Radiol 46(5), 534 (2 cases) Other Anaphylactoid reactions/Anaphylaxis ABATACEPT Trade name: Orencia (Bristol-Myers Squibb) Indications: Rheumatoid arthritis Category: T-cell co-stimulation modulator Half-life: 12–23 days Clinically important, potentially hazardous interactions with: certolizumab pegol TNF antagonists (2002): Pharand C+, Pharmacotherapy 22(3), 380 (2001): Iakovou Y+, Cardiology 95(4), 215 (1999): Guzzo JA+, Catheter Cardiovasc Interv 48, 71 Death (2006): McCorry RB+, J Invasive Cardiol 18(6), E173 (2006): Usman MH+, Heart Lung 35(6), 423 Headache Hypotension (2003): Hawkins C+, Allergy 58(7), 688 Reactions Injection-site reactions (3.6%) (2004): Dery JP+, Am J Cardiol 93(8), 979 Skin Pruritus (